MedTrace Logo

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

NCT04823702 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-01-19

No results posted yet for this study

Summary

This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function

Conditions

  • Impaired Hepatic Function

Interventions

BIOLOGICAL

Aldafermin

Biological: Aldafermin (NGM282) Subcutaneous Injection

Sponsors & Collaborators

  • NGM Biopharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • NGM Study Director · NGM Biopharmaceuticals, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-11-19
Completion
2021-11-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04823702 on ClinicalTrials.gov